platelet derived growth factor
Platelet-derived growth factor (PDGF) is one among numerous growth factors that regulate cell growth and division. In particular, PDGF plays a significant role in blood vessel formation, the growth of blood vessels from already-existing blood vessel tissue, mitogenesis, i.e. proliferation, of mesenchymal cells such as fibroblasts, osteoblasts, tenocytes, vascular smooth muscle cells and mesenchymal stem cells as well as chemotaxis, the directed migration, of mesenchymal cells. Platelet-derived growth factor is a dimeric glycoprotein that can be composed of two A subunits (PDGF-AA), two B subunits (PDGF-BB), or one of each (PDGF-AB). — Wikipedia
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Earliest trial started Jul 1, 2011 (NCT00812513)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Platelet-derived growth factor subunit ASupplementation
PDGFA supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPlatelet-derived growth factor ↗
Also known as
- platelet derived growth factor
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06390124 | Phase 4 | Sep 1, 2022 | COMPLEJO HOSPITALARIO UNIVERSITARIO, BADAJOZ |
| NCT00812513 | Phase 2 | Jul 1, 2011 | American Scitech International, Johnson and Johnson, Saint Barnabas Medical Center |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| American Scitech International | Academic/Hospital | 1 | 1 | 1 | 2011 |
| COMPLEJO HOSPITALARIO UNIVERSITARIO, BADAJOZ | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Johnson and Johnson | For profit | 1 | 0 | 1 | 2011 |
| Saint Barnabas Medical Center | Academic/Hospital | 1 | 0 | 1 | 2011 |